BSH/ISH 2016 | Treating patients with relapsed myeloma
At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland, Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of a session on what the most appropriate approach to treating patients with relapsed myeloma is. One of the key messages is the importance of using multiple drugs for treating multiple clones of the disease, according to Dr Stewart. He further discusses the combination of lenalidomide and dexamethasone as a backbone of carfilzomib, ixazomib and elotuzumab. According to Dr Stewart, randomized trials show that the combination of lenalidomide and dexamethasone and a novel agent, show improved progression-free survival (PFS) and improved overall survival (OS).
